Nikola Hudakova1, Simona Hricikova2, Amod Kulkarni2,3, Mangesh Bhide2,3, Eva Kontsekova3, Dasa Cizkova1,3. 1. Centre for Experimental and Clinical Regenerative Medicine, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia. 2. Laboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia. 3. Institute of Neuroimmunology, Slovak Academy of Sciences, 84505 Bratislava, Slovakia.
Abstract
Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all.
Coronavirus disease (n class="Disease">COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all.
Authors: Christopher Henry; Manaf Zaizafoun; Eileen Stock; Shekhar Ghamande; Alejandro C Arroliga; Heath D White Journal: Proc (Bayl Univ Med Cent) Date: 2018-10-26
Authors: Ka-Tim Choy; Alvina Yin-Lam Wong; Prathanporn Kaewpreedee; Sin Fun Sia; Dongdong Chen; Kenrie Pui Yan Hui; Daniel Ka Wing Chu; Michael Chi Wai Chan; Peter Pak-Hang Cheung; Xuhui Huang; Malik Peiris; Hui-Ling Yen Journal: Antiviral Res Date: 2020-04-03 Impact factor: 5.970
Authors: Yumiko Imai; Keiji Kuba; Shuan Rao; Yi Huan; Feng Guo; Bin Guan; Peng Yang; Renu Sarao; Teiji Wada; Howard Leong-Poi; Michael A Crackower; Akiyoshi Fukamizu; Chi-Chung Hui; Lutz Hein; Stefan Uhlig; Arthur S Slutsky; Chengyu Jiang; Josef M Penninger Journal: Nature Date: 2005-07-07 Impact factor: 49.962
Authors: Hongchao Pan; Richard Peto; Ana-Maria Henao-Restrepo; Marie-Pierre Preziosi; Vasee Sathiyamoorthy; Quarraisha Abdool Karim; Marissa M Alejandria; César Hernández García; Marie-Paule Kieny; Reza Malekzadeh; Srinivas Murthy; K Srinath Reddy; Mirta Roses Periago; Pierre Abi Hanna; Florence Ader; Abdullah M Al-Bader; Almonther Alhasawi; Emma Allum; Athari Alotaibi; Carlos A Alvarez-Moreno; Sheila Appadoo; Abdullah Asiri; Pål Aukrust; Andreas Barratt-Due; Samir Bellani; Mattia Branca; Heike B C Cappel-Porter; Nery Cerrato; Ting S Chow; Najada Como; Joe Eustace; Patricia J García; Sheela Godbole; Eduardo Gotuzzo; Laimonas Griskevicius; Rasha Hamra; Mariam Hassan; Mohamed Hassany; David Hutton; Irmansyah Irmansyah; Ligita Jancoriene; Jana Kirwan; Suresh Kumar; Peter Lennon; Gustavo Lopardo; Patrick Lydon; Nicola Magrini; Teresa Maguire; Suzana Manevska; Oriol Manuel; Sibylle McGinty; Marco T Medina; María L Mesa Rubio; Maria C Miranda-Montoya; Jeremy Nel; Estevao P Nunes; Markus Perola; Antonio Portolés; Menaldi R Rasmin; Aun Raza; Helen Rees; Paula P S Reges; Chris A Rogers; Kolawole Salami; Marina I Salvadori; Narvina Sinani; Jonathan A C Sterne; Milena Stevanovikj; Evelina Tacconelli; Kari A O Tikkinen; Sven Trelle; Hala Zaid; John-Arne Røttingen; Soumya Swaminathan Journal: N Engl J Med Date: 2020-12-02 Impact factor: 91.245
Authors: Maroun Khoury; Patricia R M Rocco; Donald G Phinney; Mauro Krampera; Ivan Martin; Sowmya Viswanathan; Jan A Nolta; Katarina LeBlanc; Jacques Galipeau; Daniel J Weiss Journal: Cytotherapy Date: 2020-04-17 Impact factor: 5.414
Authors: Catherine Mark; Sumit Gupta; Angela Punnett; Julia Upton; Julia Orkin; Adelle Atkinson; Lindsay Clarke; Alice Heisey; Christine McGovern; Sarah Alexander Journal: Pediatr Blood Cancer Date: 2021-08-16 Impact factor: 3.838